Scalable magnet geometries enhance tumour targeting of magnetic nano-carriers

Mohseni, Matin; Connell, John; Patrick, P. Stephen; Rj, Baker; Yu, Yichao; Siow, Bernard; Zaw-Thin, M; Kalber, Tammy; Pankhurst, Quentin A.; Lythgoe, Mark F.

doi:10.1016/j.matdes.2020.108610

Cited by 16 publications

(5 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, due to their comparable sizes with various functional biomolecules, magnetic nanoparticles (MNPs) do not present any extravasations from normal vessels and accumulate at the pathological sites via the enhanced permeability and retention effect. The MNPs possess superparamagnetism, high field irreversibility, a high saturation field, and extra anisotropy contributions that can be further manipulated by an external magnetic field gradient and the ability to conjugate with many biological and drug entities, which lays a platform for multifunctional utility, such as contrast agents in magnetic resonance imaging, 113 site-specific magnetic targeting, 114 magnetic hyperthermia treatment, 115 multimodal imaging, 116 magnetic-field-dependent controlled drug delivery, 117 magnetofection, and gene delivery. 118 However, MNPs have hydrophobic surfaces, and due to hydrophobic interactions, these particles tend to agglomerate, resulting in poor performance due to the formation of larger clusters.…”

Section: Materials Nanoarchitectonics: a Paradigm Shift To Create Bio...mentioning

confidence: 99%

Nanoarchitectonics horizons: materials for life sciences

et al. 2022

View full text Add to dashboard Cite

show abstract

Section: Materials Nanoarchitectonics: a Paradigm Shift To Create Bio...mentioning

confidence: 99%

Nanoarchitectonics horizons: materials for life sciences

et al. 2022

View full text Add to dashboard Cite

show abstract

“…It is possible to target MNCs toward the regions of the strongest field strength by applying nonuniform CMFs. The spatial organization of MNs in the tumor can be directed by appropriately designed patterns of the field gradient (Mohseni et al, 2020; Tracy & Crawford, 2013). The arrangement of the magnetic field gradient for nanotherapy is often achieved through a set of multiple permanent magnets (Subramanian et al, 2019) or a magnetic‐dipole applicator (V. E. Orel, Kruchkov, et al, 2015).…”

Section: Limitations and Challenges For Future Clinical Translationmentioning

confidence: 99%

Nanotherapy based on magneto‐mechanochemical modulation of tumor redox state

Orel

Papazoglou

Tsagkaris³

et al. 2022

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Magnetic nanoparticles (MNs) are typically used as contrast agents for magnetic resonance imaging or as drug carriers with a remotely controlled delivery to the tumor. However, they can also potentiate the action of anticancer drugs under the influence of applied constant magnetic (CMFs) and electromagnetic fields (EMFs). This review demonstrates the role of magneto‐mechanochemical effects produced by MNs alone and loaded with anticancer agents (MNCs) in response to CMFs and EMFs for modulation of tumor redox state. The combined treatment is suggested to act by two mechanisms: spin‐dependent electron transport propagates free radical chain reactions, while magnetomechanical interactions cause conformational changes in drug molecules loaded onto MNs and generate reactive oxygen species (ROS). By adjusting the parameters of CMFs and EMFs during the magneto‐mechanochemical synthesis and subsequent treatment, it is possible to modulate ROS production and switch redox signaling involved in ERK1/2 and NF‐κB pathways from initiation of tumor growth to inhibition. Observations of tumor volume in different animal models and treatment combinations reported a 6%–70% reduction as compared with conventional drugs. Despite these results, there is a general lack of research in magnetic nanotheranostics that link redox changes across multiple levels of organization in the tumor‐bearing host. Further multidisciplinary studies with more focus on the relationship between the electron transport processes in biomolecules and their effects on the tumor‐host interaction should accelerate the clinical translation of magnetic nanotheranostics. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Therapeutic Approaches and Drug Discovery > Emerging Technologies Nanotechnology Approaches to Biology > Nanoscale Systems in Biology

show abstract

“…Magnetic drug targeting (MDT) is a promising method of concentrating magnetic nanoparticles (MNP) such as iron oxide at a target site in vivo [1][2][3][4][5]. The pioneering idea proposed by Freeman et al (1960), suggested MNP can be transported through the vascular system and concentrated to a particular point in the body with the aid of a magnetic field [6].…”

Section: Introductionmentioning

confidence: 99%

Development of a Personalised Device for Systemic Magnetic Drug Targeting to Brain Tumours

Patel¹,

Alghamdi²,

Shaw³

et al. 2023

Nanotheranostics

View full text Add to dashboard Cite

Delivering therapies to deeply seated brain tumours (BT) is a major clinical challenge. Magnetic drug targeting (MDT) could overcome this by rapidly transporting magnetised drugs directly into BT. We have developed a magnetic device for application in murine BT models using an array of neodymium magnets with a combined strength of 0.7T. In a closed fluidic system, the magnetic device trapped magnetic nanoparticles (MNP) up to distances of 0.8cm. In mice, the magnetic device guided intravenously administered MNP (<50nm) from the circulation into the brain where they localised within mouse BT. Furthermore, MDT of magnetised Temozolomide (TMZ mag+ ) significantly reduced tumour growth and extended mouse survival to 48 days compared to the other treatment groups. Using the same principles, we built a proof of principle scalable magnetic device for human use with a strength of 1.1T. This magnetic device demonstrated trapping of MNP undergoing flow at distances up to 5cm. MDT using our magnetic device provides an opportunity for targeted delivery of magnetised drugs to human BT.

show abstract

Scalable magnet geometries enhance tumour targeting of magnetic nano-carriers

Cited by 16 publications

References 49 publications

Nanoarchitectonics horizons: materials for life sciences

Nanoarchitectonics horizons: materials for life sciences

Nanotherapy based on magneto‐mechanochemical modulation of tumor redox state

Development of a Personalised Device for Systemic Magnetic Drug Targeting to Brain Tumours

Contact Info

Product

Resources

About